Home Cart Sign in  
Chemical Structure| 138402-11-6 Chemical Structure| 138402-11-6

Structure of Irbesartan
CAS No.: 138402-11-6

Chemical Structure| 138402-11-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Irbesartan is a selective and competitive nonpeptide angiotensin II antagonist with antihypertensive activity.

Synonyms: BMS-186295; SR-47436

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Irbesartan

CAS No. :138402-11-6
Formula : C25H28N6O
M.W : 428.53
SMILES Code : C3=C(CN1C(=O)C2(N=C1CCCC)CCCC2)C=CC(=C3)C4=CC=CC=C4C5=N[NH]N=N5
Synonyms :
BMS-186295; SR-47436
MDL No. :MFCD00864464
InChI Key :YOSHYTLCDANDAN-UHFFFAOYSA-N
Pubchem ID :3749

Safety of Irbesartan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Irbesartan

GPCR

Isoform Comparison

Biological Activity

Target
  • AT1 receptor

    AT1 receptor, IC50:1.3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
GEM-resistant BxPC-3 cell line 1 μM 72 h Evaluate the effect of Irbesartan on GEM-resistant BxPC-3 cell line, results showed that Irbesartan significantly reversed GEM resistance. PMC10157938
PDAC organoids (PDO02#) 1 μM 72 h Evaluate the effect of Irbesartan on PDAC organoid apoptosis, results showed that the combined regimen significantly induced the expression of cleaved-caspase3 and cleaved-caspase7. PMC10157938
PDAC organoids (PDO01#) 1 μM 72 h Evaluate the effect of Irbesartan on PDAC organoid apoptosis, results showed that the combined regimen significantly induced the expression of cleaved-caspase3 and cleaved-caspase7. PMC10157938
Rat aortic smooth muscle cells (SMC) 1 μM 24 hours Irbesartan downregulated Ang II-induced DNA-PKcs expression PMC10520570
Lung fibroblasts 30 mg/mL 24 hours To evaluate the effect of macrophage exosomes on collagen synthesis in lung fibroblasts. Results showed that macrophage exosomes significantly increased the expression of α-collagen I in lung fibroblasts. PMC8478379

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Akita/ACE2KO mice Oral 50 mg/kg/d Once daily for 1 month Treatment with irbesartan rescued the systolic dysfunction in Akita/ACE2KO mice, normalized altered signaling pathways, flow-mediated dilation, and the increased oxidative stress in the cardiovascular system. PMC3746191
NOD/SCID and BALB/c-nude mice PDOX mouse models and KPC genetically engineered mouse models Oral gavage 20 mg/kg Twice a week for 8 weeks Evaluate the therapeutic effect of Irbesartan in vivo on PDAC, results showed that the combination regimen significantly reduced tumor burden and prolonged survival. PMC10157938
C57BL/6J mice Cerebral malaria model Oral gavage 50 mg/kg/d Once daily until complete clearance of parasitemia (days 11-16 after infection) To investigate the protective effect of Irbesartan as adjunctive therapy for cerebral malaria, results showed that Irbesartan significantly increased survival rates in mice. PMC5096829
Mice Ang II-induced vascular remodeling model Intragastric administration 30 mg/kg/d Every day for 2 weeks Irbesartan alleviated Ang II-induced vascular remodeling and hypertension PMC10520570
C57 mice Bleomycin-induced pulmonary fibrosis model Oral administration in drinking water 2 mg/kg For 4 weeks To evaluate the effect of irbesartan on exosome-induced pulmonary fibrosis. Results showed that irbesartan reversed the fibrotic features induced by exosomes and reduced the levels of Ang II and AT1R. PMC8478379
Mice BAPN-induced thoracic aortopathy model Oral 50 mg/kg/day Once daily for 4 weeks To evaluate the effect of irbesartan on BAPN-induced thoracic aortopathies; results showed irbesartan did not ameliorate aortic rupture and dilatation PMC9492637

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00741702 Hypertension ... More >>Diabetes Mellitus Less << Not Applicable Completed - -
NCT01195818 Sickle Cell Disease Not Applicable Completed - France ... More >> Centre de la Drépanocytose, Service de Médecine Interne. Hôpital Tenon, 4 Rue de la Chine Paris, France, 75020 Less <<
NCT01715207 Marfan Syndrome Phase 3 Completed - Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less <<
NCT01715207 - Completed - -
NCT02973035 Hypertension Phase 4 Recruiting June 2019 Korea, Republic of ... More >> Busan Baik Hospital Recruiting Busan, Korea, Republic of Contact: Jeong-Suk Seo, M.D.       orifilter@hanmail.net    Busan University Hospital Recruiting Busan, Korea, Republic of Contact: Yong-Hyun Park       nadroj@chol.com    Chungnam University Hospital Recruiting Daejeon, Korea, Republic of Contact: Jae-Hyung Park, M.D.       jaehpark@cnuh.co.kr    Asan Medical Center Recruiting Seoul, Korea, Republic of Contact: Duk-Hyun Kang, M.D.       dhkang@amc.seoul.kr Less <<
NCT00361023 Type 2 Diabetes ... More >> Diabetic Nephropathy Less << Not Applicable Completed - -
NCT01805362 Chronic Kidney Disease Not Applicable Unknown February 2017 France ... More >> Department of Nephrology, Nice University Hospital Recruiting Nice, France, 06000 Contact: vincent Esnault, MD       esnault.v@chu-nice.fr    Principal Investigator: Vincent Esnault, MD Less <<
NCT00212901 Diabetic Kidney Disease Not Applicable Completed - Canada, Ontario ... More >> The Ottawa Hospital Ottawa, Ontario, Canada, K1H 7W9 Less <<
NCT00794963 Metabolic Syndrome Not Applicable Terminated(Difficulty recruiti... More >>ng) Less << - United States, New York ... More >> Zucker Hillside Hospital Glen Oaks, New York, United States, 11004 Less <<
NCT00794963 - Terminated(Difficulty recruiti... More >>ng) Less << - -
NCT00180024 Healthy Subjects Not Applicable Completed - Germany ... More >> Institute of Clinical Pharmacology, Medical Faculty, University of Technology Dresden, Germany, 01307 Less <<
NCT00657059 IgA Nephropathy Phase 3 Active, not recruiting April 2019 China, Guangdong ... More >> The 1st Affiliated Hospital, Sun Yet-sen University Guangzhou, Guangdong, China, 510080 Less <<
NCT01500590 Diabetes Hype... More >>rtensive Disease Less << Phase 4 Active, not recruiting August 2019 China ... More >> Hospital Authority, HKEC, FM&PHC Hong Kong, China Less <<
NCT02644486 Obesity and Glomerulopathy Not Applicable Terminated(difficulty in enrol... More >>lment) Less << - China, Jiangsu ... More >> Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine Nanjing, Jiangsu, China, 210002 Less <<
NCT02380625 Ebola Virus Disease Phase 1 Phase 2 Unknown March 2016 -
NCT00106561 Kidney Disease ... More >> Diabetic Nephropathy Glomerulonephritis Proteinuria Less << Phase 2 Phase 3 Completed - Australia, Victoria ... More >> Department of Nephrology, The Royal Melbourne Hospital Melbourne, Victoria, Australia, 3050 Less <<
NCT00224549 Hypertension Phase 4 Completed - France ... More >> Investigation Clinical Center European Georges Pompidou Hospital Paris, Ile de France, France, 75015 Less <<
NCT00005010 End-Stage Renal Disease ... More >> Chronic Allograft Nephropathy Less << Phase 3 Completed - United States, Maryland ... More >> Ilene Blechman-Krom Rockville, Maryland, United States, 20850 Less <<
NCT03016832 Diabetic Kidney Disease Early Phase 1 Unknown December 2018 China, Jiangsu ... More >> Jiangsu Province Hospital of TCM Recruiting Nanjing, Jiangsu, China Contact: Wei Sun    +86 13505199801    jssunwei@163.com Less <<
NCT01968759 Chronic Kidney Disease Phase 2 Completed - Italy ... More >> Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 Azienda Ospedaliera "Bianchi-Melacrino-Morelli" c/o Ospedali Riuniti U.O. Nefrologia, Dialisi e Trapianto Reggio Calabria, Italy Less <<
NCT00635232 - Completed - -
NCT00742066 Hypertension ... More >>Insulin Resistance Microcirculation Less << Not Applicable Unknown July 2009 Netherlands ... More >> University Hospital Maastricht Maastricht, P.O. Box 5800, Netherlands, 6202 AZ Less <<
NCT00249873 Atrial Fibrillation ... More >> Vascular Risk Less << Phase 3 Completed - -
NCT00243178 Atrial Fibrillation ... More >> Vascular Risk Less << Phase 3 Terminated - -
NCT00635232 Hypertension Phase 2 Completed - -
NCT02721342 - Recruiting March 2019 Italy ... More >> Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò Recruiting Ranica, Bergamo, Italy, 24020 Contact: Erica Daina, MD       erica.daina@marionegri.it    Ospedale Morgagni - Pierantoni - U.O. Nefrologia e Dialisi Recruiting Forlì, Forli', Italy, 47011 Contact: Giovanni Mosconi, MD       giovanni.mosconi@ausl.fo.it    Asl 6 Sanluri-P.O. Nostra Signora di Bonaria - U.O. Nefrologia e Dialisi Recruiting San Gavino- Monreale, Medio Campidano - VS, Italy, 09037 Contact: Maria Cristina Mereu, MD       mariacristina.mereu@asl6sanluri.it    Ospedale C.G. Mazzoni Zona 13 ASUR Marche - U.O. Nefrologia e Dialisi Recruiting Ascoli Piceno, Italy, 63100 Contact: Mauro Ragaiolo, MD       m.ragaiolo@asl13.marche.it    AORN Moscati - Avellino - U.O. Nefrologia e Dialisi Recruiting Avellino, Italy, 83100 Contact: Walter De Simone, MD       wadesimone@aosgmoscati.av.it    A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi Recruiting Bergamo, Italy, 20147 Contact: Piero Ruggenenti, MD       pruggenenti@hpg23.it    A.O. Papa Giovanni XXIII Bergamo - U.O. Diabetologia Recruiting Bergamo, Italy, 20147 Contact: Roberto Trevisan, MD       rtrevisan@hpg23.it    Azienda Ospedaliera G. Brotzu - U.O. Nefrologia e Dialisi Recruiting Cagliari, Italy, 09100 Contact: Antonello Pani, MD       antonellopani@aob.it    Ospedale Campo di Marte - USL 2 - U.O. Nefrologia Recruiting Lucca, Italy, 55100 Contact: Alberto Rosati, MD       arosati@usl2.toscana.it    ARNAS Ospedale Civico Di Cristina Benfratelli - U.O. Nefrologia e Dialisi Recruiting Palermo, Italy, 90127 Contact: Carlo Giammarresi, MD       cgiammer@tin.it    Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Università degli Studi di Palermo - Dipartimento Malattie Cardiovascolari e Nefrourologiche - U.O. Tecniche Dialitiche Recruiting Palermo, Italy, 90129 Contact: Maurizio Li Vecchi, MD       livecchi@unipa.it    Azienda Ospedaliera Universitaria Pisana - U.O. Nefrologia e Dialisi 2 Recruiting Pisa, Italy, 56126 Contact: Giuliano Barsotti, MD       g.barsotti@med.unipi.it    Ospedale di Circolo Fondazione Macchi - U.O. Nefrologia e Dialisi Recruiting Varese, Italy, 21100 Contact: Gian Maria Frattini, MD       gianmaria.frattini@ospedale.varese.it Less <<
NCT00343551 Essential Hypertension Phase 3 Completed - Germany ... More >> Investigative Centers, Germany Switzerland Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT01360710 Abdominal Obesity ... More >> Hypertension Less << Phase 4 Unknown - Australia, Victoria ... More >> BakerIDI Heart and Diabetes Institute Recruiting Prahran, Victoria, Australia, 3004 Contact: Markus Schlaich       markus.schlaich@bakeridi.edu.au Less <<
NCT01109212 Diabetic Nephropathy Phase 2 Completed - Italy ... More >> The Mario Negri Institute for Pharmacological Research- Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 Azienda Ospedaliera di Treviglio-Caravaggio - Unità Operativa Malattie Metaboliche e Diabetologia Treviglio, Bergamo, Italy, 24047 Azienda Ospedaliera OO.RR. Bergamo - Unità Operativa Diabetologia Bergamo, Italy, 24128 IRCCS Fondazione Centro S. Raffaele del Monte Tabor- Unità Operativa Medicina Generale Milano, Italy, 20132 Ist. Patologia Medica e metodologia Clinica - Università di Sassari Sassari, Italy, 7100 Slovenia University Medical Center Dpt Endocrinology Diabetes and Metabolic Diseases- Diabetology Unit Ljubljana, Slovenia, 1000 Less <<
NCT03493685 Focal Segmental Glomeruloscler... More >>osis Less << Phase 3 Recruiting December 2022 -
NCT01519297 Preeclampsia|Pregnancy Induced... More >> Hypertension Less << SUSPENDED 2025-07-19 Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States Less <<
NCT03762850 Immunoglobulin A Nephropathy Phase 3 Not yet recruiting April 2023 -
NCT00249873 - Completed - -
NCT01613118 Focal Segmental Glomeruloscler... More >>osis Less << Phase 2 Active, not recruiting August 2021 -
NCT00500604 Hypertension Phase 4 Completed - Egypt ... More >> Sanofi-Aventis Administrative Office Cairo, Egypt Hong Kong Sanofi-Aventis Administrative Office Hong Kong, Hong Kong India Sanofi-Aventis Administrative Office Mumbai, India Indonesia Sanofi-Aventis Administrative Office Jakarta, Indonesia Korea, Republic of Sanofi-Aventis Administrative Office Seoul, Korea, Republic of Malaysia Sanofi-Aventis Administrative Office Kuala Lumpur, Malaysia Morocco Sanofi-Aventis Administrative Office Casablanca, Morocco Pakistan Sanofi-Aventis Administrative Office Karachi, Pakistan Philippines Sanofi-Aventis Administrative Office Makati City, Philippines Singapore Sanofi-Aventis Administrative Office Singapore, Singapore Taiwan Sanofi-Aventis Administrative Office Taipei, Taiwan Thailand Sanofi-Aventis Administrative Office Bangkok, Thailand Tunisia Sanofi-Aventis Administrative Office Megrine, Tunisia Vietnam Sanofi-Aventis Administrative Office Ho Chi Minh City, Vietnam Less <<
NCT01238705 Hypertension ... More >>Sexual Dysfunction Less << Phase 4 Unknown November 2010 China, Gansu ... More >> The Second Hospital of Lanzhou University Recruiting Lanzhou, Gansu, China, 730000 Contact: Ruixin Ma, Doctor    +86 13893102690    mrxdr@sina.com    Contact: Jing Yu, Professor    +86 13893607559    yujing2304@126.com    Principal Investigator: Jing Yu, Professor          Sub-Investigator: Ruixin Ma, Doctor Less <<
NCT02597361 Ehlers-Danlos Syndrome, Vascul... More >>ar Type Less << Phase 3 Recruiting April 2020 France ... More >> CHU DE BORDEAUX - Hopital Saint Andre Recruiting Bordeaux, France, 33075 Contact: Joel CONSTANS, MD,PHD    +33 5 56 79 57 16    joel.constans@chu-bordeaux.fr    CHU DE LYON - Hopital Femme Mere Enfant Recruiting Bron, France, 69500 Contact: Sophie DUPUIS-GIROD, MD,PHD    +33 4 27 85 65 24    sophie.dupuis-girod@chu-lyon.fr    CHU DE CAEN - Hopital Cote de Nacre Recruiting Caen, France, 14033 Contact: Damien LANEELLE, MD,PHD    +33 2 31 06 53 27    laneelle-d@chu-caen.fr    CHU DE TOURS - Hopital Trousseau Not yet recruiting Chambray-les-Tours, France, 37044 Contact: Gabriela GEORGESCOU, MD    +33 2 47 47 46 25    g.georgescou@chu-tours.fr    CHU DE GRENOBLE - Hopital Albert Michallon Recruiting Grenoble, France, 38043 Contact: Christophe SEINTURIER, MD,PHD    +33 4 76 76 89 60    cseinturier@chu-grenoble.fr    CHU DE GRENOBLE - Hopital Couple Enfant Not yet recruiting Grenoble, France, 38043 Contact: Pierre-Simon JOUK, MD,PHD    +33 7 76 76 72 85    psjouk@chu-grenoble.fr    CHRU DE LILLE - Hopital Claude Huriez Recruiting Lille, France, 59000 Contact: Marc LAMBERT, MD    +33 3 20 44 42 96    marc.lambert@chru-lille.fr    CHU DE LYON - Hopital Edouard Herriot Not yet recruiting Lyon, France, 69003 Contact: Jacques NINET, MD,PHD    +33 4 72 11 75 71    jacques.ninet@chu-lyon.fr    AP-HM - Hopital de la Timone Recruiting Marseille, France, 13385 Contact: Laurence BAL-THEOLEYRE, MD    +33 4 91 38 81 20    laurence.bal@ap-hm.fr    CHU DE MONTPELLIER - Hopital Saint Eloi Recruiting Montpellier, France, 34295 Contact: Isabelle QUERE, MD,PHD    +33 67 33 70 25    i-quere@chu-montpellier.fr    CHU DE NANTES - Hopital Hotel-Dieu Not yet recruiting Nantes, France, 44300 Contact: Marc-Antoine PISTORIUS, MD    +33 2 40 08 33 34    marc.pistorius@chu-nantes.fr    AP-HP - Hopital Europeen Georges-Pompidou Recruiting Paris, France, 75015 Contact: Xavier JEUNEMAITRE, MD,PHD    +33 1 56 09 38 80    xavier.jeunemaitre@aphp.fr    Contact: Michael FRANK, MD    +33 1 56 09 50 40    michael.frank@aphp.fr    CHU DE TOULOUSE - Hopital Purpan Not yet recruiting Toulouse, France, 31059 Contact: Sophie JULIA, MD    +33 5 61 77 90 55    julia.s@chu-toulouse.fr    CHU DE TOULOUSE - Hopital Rangueil Recruiting Toulouse, France, 31059 Contact: Alessandra BURA-RIVIERE, MD,PHD    +33 5 61 32 24 38    bura-riviere.a@chu-toulouse.fr    CHRU DE NANCY - Institut Lorrain du Coeur et des Vaisseaux Recruiting Vandoeuvre-les-Nancy, France, 54500 Contact: Denis WAHL, MD,PHD    +33 3 83 15 36 14    d.wahl@chu.nancy.fr Less <<
NCT00219115 Hypertension Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Investigative Centers, Germany Less <<
NCT00264212 Hypertension Phase 4 Completed - Chile ... More >> Sanofi-Aventis Santiago, Chile China Sanofi-Aventis Shangai, China Indonesia Sanofi-Aventis Jakarta, Indonesia Korea, Republic of Sanofi-Aventis Seoul, Korea, Republic of Mexico Sanofi-Aventis Mexico, Mexico Philippines Sanofi-Aventis Manila, Philippines Taiwan Sanofi-Aventis Taipei, Taiwan Thailand Sanofi-Aventis Bangkok, Thailand Less <<
NCT03006796 - Recruiting June 2019 Russian Federation ... More >> City Hospital №5 Recruiting Moscow, Russian Federation, 107015 Contact: Elena Y Shupenina, PhD    +74992684459 Less <<
NCT01949233 Marfan Syndrome Phase 2 Unknown December 2017 United Kingdom ... More >> John Radcliffe Hospital Recruiting Oxford, Oxfordshire, United Kingdom, OX3 9DU Sub-Investigator: Edward Blair, MBChB MRCP          Sub-Investigator: Paul Wordsworth, MB FRCP          University of Oxford Recruiting Oxford, Oxfordshire, United Kingdom, OX3 9DU Sub-Investigator: Alex Pitcher, DPhil, MA, BM BCh, MRCP          Sub-Investigator: Andrew Lewis, MB BS MRes MRCP          Sub-Investigator: Hayley Harvey          Sub-Investigator: Stefan Neubauer, MD FRCP FACC FMedSci          Sub-Investigator: Paul Leeson          Sub-Investigator: Jacqueline Birks Less <<
NCT01992796 Severe Sepsis PHASE3 UNKNOWN 2025-01-17 Università di Salerno, Salerno... More >>, Italy Less <<
NCT00660309 Type 2 Diabetes Mellitus Phase 4 Completed - United States, Massachusetts ... More >> Novartis Investigator Site Boston, Massachusetts, United States, 02115 Less <<
NCT00350038 Hypertension ... More >>Dyslipidemia Less << Phase 4 Completed - Hungary ... More >> Sanofi-aventis Budapest, Hungary Less <<
NCT01082835 - Unknown August 2010 China, Beijing ... More >> Beijing Medical University ,Dongzhimen Hospital Not yet recruiting Beijing, Beijing, China Contact: Weixing Lu    0086-013601067938    weixinglu918@sina.com    Beijing Medical University,Dongfang Hospital Not yet recruiting Beijing, Beijing, China Contact: Qian Lin    0086-013910565673    dfluyao@126.com    China Academy of Chinese Medical Sciences,Guang'anmen Hospital Not yet recruiting Beijing, Beijing, China Contact: Qiang Zhou    0086-015101016416    tiantianlanzhouqiang@126.com    Chinese Academy of Medical Sciences Fu Wai Cardiovascular Hospital Not yet recruiting Beijing, Beijing, China Contact: Jianfeng Huang    0086-010-88396403    jianfhuang918@sina.com    Capital University of Medical, Anzhen Hospital Not yet recruiting Beijng, Beijing, China Contact: Zhenqiu Yu    0086-010-64456577    yuzhenqiu@yahoo.com.cn Less <<
NCT00171080 Hypertension Phase 3 Completed - Germany ... More >> Investigative Centers, Germany Switzerland Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT00950066 Hypertension Phase 2 Completed - India ... More >> Sanofi-Aventis Administrative Office Mumbai, India Korea, Republic of Sanofi-Aventis Administrative Office Seoul, Korea, Republic of Philippines Sanofi-Aventis Administrative Office Makati City, Philippines Taiwan Sanofi-Aventis Administrative Office Taipei, Taiwan Less <<
NCT00185055 Healthy Phase 4 Completed - -
NCT00154024 Healthy Subjects Not Applicable Completed - Germany ... More >> Institute of Clinical Pharmacology, Medical Faculty, University of Technology Dresden, Germany, 01307 Less <<
NCT00561964 Hypertension Phase 3 Completed - -
NCT00708344 Hypertension Phase 4 Completed - Algeria ... More >> Sanofi-Aventis Administrative Office Algiers, Algeria Argentina Sanofi-Aventis Administrative Office Buenos Aires, Argentina Brazil Sanofi-Aventis Administrative Office Sao Paulo, Brazil Colombia Sanofi-Aventis Administrative Office Bogota, Colombia Ecuador Sanofi-Aventis Administrative Office Quito, Ecuador Egypt Sanofi-Aventis Administrative Office Cairo, Egypt Guatemala Sanofi-Aventis Administrative Office Guatemala City, Guatemala Lebanon Sanofi-Aventis Administrative Office Beirut, Lebanon Mexico Sanofi-Aventis Administrative Office Col. Coyoacan, Mexico Morocco Sanofi-Aventis Administrative Office Casablanca, Morocco Panama Sanofi-Aventis Administrative Office Panama, Panama Peru Sanofi-Aventis Administrative Office Lima, Peru Saudi Arabia Sanofi-Aventis Administrative Office Jeddah, Saudi Arabia Tunisia Sanofi-Aventis Administrative Office Megrine, Tunisia United Arab Emirates Sanofi-Aventis Administrative Office Dubaï, United Arab Emirates Venezuela Sanofi-Aventis Administrative Office Caracas, Venezuela Less <<
NCT00125645 Myocardial Infarction Phase 4 Completed - Denmark ... More >> Kardiologisk Klinik, Centralsygehuset Esbjerg/Varde Esbjerg, Denmark, 6700 Less <<
NCT01442987 Hypertension ... More >>Hyperlipidemia Less << Phase 3 Completed - Korea, Republic of ... More >> 16 institutions including Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT00660309 - Completed - -
NCT03627715 Diabetic Kidney Disease Phase 2 Recruiting October 2019 Australia, New South Wales ... More >> Renal Research Recruiting Gosford, New South Wales, Australia Contact: Simon Rogers          Liverpool Hospital Recruiting Liverpool, New South Wales, Australia, 2170 Contact: Michael Suranyi          Royal North Shore Hospital Recruiting St Leonards, New South Wales, Australia, 2065 Contact: Carol Pollock          Westmead Hospital Recruiting Westmead, New South Wales, Australia, 2145 Contact: Richard Phoon          Australia, Queensland Sunshine Coast University Hospital Not yet recruiting Birtinya, Queensland, Australia, 4575 Contact: Nicholas Gray          Princess Alexandra Hospital Recruiting Woolloongabba, Queensland, Australia, 4102 Contact: David Mudge          Australia, Victoria Boxhill Hospital Recruiting Box Hill, Victoria, Australia, 3128 Contact: Matthew Roberts          Austin Hospital Recruiting Heidelberg, Victoria, Australia, 3084 Contact: David Power          Sunshine Hospital Recruiting Melbourne, Victoria, Australia, 3021 Contact: Craig Nelson          Epworth Hospital Recruiting Richmond, Victoria, Australia, 3121 Contact: Ian Fraser Less <<
NCT00095238 Congestive Heart Failure Phase 3 Completed - -
NCT00265642 Hepatitis C, Chronic Phase 3 Completed - France ... More >> CHU Angers, Service d'hépato-gastroentérologie Angers, France, 49933 cedex 09 Less <<
NCT00335673 Hypertension Phase 4 Completed - Egypt ... More >> Sanofi-Aventis Administrative Office Cairo, Egypt Less <<
NCT03649152 Focal Segmental Glomeruloscler... More >>osis Less << Phase 2 Recruiting December 2019 Australia, New South Wales ... More >> Renal Research Recruiting Gosford, New South Wales, Australia, 2250 Contact: Simon Roger          Liverpool Hospital Recruiting Liverpool, New South Wales, Australia, 2170 Contact: Michael Suranyi          Royal North Shore Hospital Recruiting St Leonards, New South Wales, Australia, 2065 Contact: Carol Pollock          Westmead Recruiting Westmead, New South Wales, Australia, 2145 Contact: Richard Phoon          Australia, Queensland Sunshine Coast University Hospital Recruiting Birtinya, Queensland, Australia, 4575 Contact: Nicholas Gray          Princess Alexandra Hospital Recruiting Woolloongabba, Queensland, Australia, 4102 Contact: David Mudge          Australia, Victoria Box Hill Hospital Recruiting Box Hill, Victoria, Australia, 3128 Contact: Matthew Roberts          Austion Hospital Recruiting Heidelberg, Victoria, Australia, 3084 Contact: David Power          Sunshine Hospital Recruiting Melbourne, Victoria, Australia, 3021 Contact: Craig Nelson          Epworth Hospital Recruiting Richmond, Victoria, Australia, 3121 Contact: Ian Fraser Less <<
NCT00095238 - Completed - -
NCT00347087 Chronic Heart Failure PHASE4 COMPLETED 2025-06-07 Applied Cachexia Research, Car... More >>diology Dept. Charite Medical School, Virchow Klinikum, Berlin, Germany Less <<
NCT01625494 Hypertension Phase 3 Completed - Russian Federation ... More >> Sanofi-Aventis Administrative Office Moscow, Russian Federation Less <<
NCT00296218 Myocardial Ischemia|Hypertensi... More >>on Less << PHASE3 COMPLETED - Sanofi-Aventis, Bridgewater, N... More >>ew Jersey, United States|Sanofi-Aventis, Brussels, Belgium|Sanofi-Aventis, Laval, Canada|Sanofi-Aventis, Paris, France|Sanofi-Aventis, Berlin, Germany|Sanofi-Aventis, Budapest, Hungary|Sanofi-Aventis, Milan, Italy|Sanofi-Aventis, Gouda, Netherlands|Sanofi-Aventis, Barcelona, Spain|Sanofi-Aventis, Meyrin, Switzerland|Sanofi-Aventis, Guildford, United Kingdom Less <<
NCT00670566 Hypertension Phase 4 Completed - China ... More >> Sanofi-Aventis Administrative Office Shanghai, China Less <<
NCT02148991 - Completed - Greece ... More >> Georgios Gennimatas General State Hospital Athens, Holargos, Greece, 11527 Georgios Gennimatas General State Hospital Athens, Greece, 10682 Less <<
NCT00225667 Atrial Fibrillation|Hypertensi... More >>on Less << PHASE3 UNKNOWN 2025-07-07 Population Health Research Ins... More >>titute of McMaster University, Hamilton, Ontario, L8L 2X2, Canada Less <<
NCT00529750 Hypertension Phase 4 Completed - -
NCT00283036 Hypertension PHASE4 COMPLETED - Sanofi-Aventis, Alger, Algeria
NCT00562809 Hypertension Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT01858610 Healthy Not Applicable Completed - Egypt ... More >> Pharmaceutics Department, Faculty of Pharmacy, Damanhour University Damanhour, Egypt Less <<
NCT00320879 Type 2 Diabetes ... More >> Microalbuminuria Less << Phase 4 Completed - Denmark ... More >> Steno Diabetes Center Gentofte, Copenhagen, Denmark, 2820 Less <<
NCT00464880 Diabetes Type 2 Phase 1 Phase 2 Completed - Denmark ... More >> Novartis Gentofte, Denmark, 2820 Less <<
NCT00362037 Hypertension Phase 4 Completed - Egypt ... More >> Sanofi-Aventis Administrative Office Cairo, Egypt Less <<
NCT00317915 Type 2 Diabetes ... More >> Microalbuminuria Hypertension Less << Phase 3 Completed - -
NCT00095550 Hypertension Phase 3 Completed - -
NCT00152698 Hypercholesterolemia PHASE3 WITHDRAWN 2025-12-09 CRC, Medizinsiche Klinik 4, Ne... More >>phrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Bavaria, 91054, Germany Less <<
NCT00110422 Metabolic Syndrome ... More >> Hypertension Less << Phase 4 Completed - France ... More >> Local Institution Angers, France Local Institution Nantes, France Local Institution Tierce, France Germany Local Institution Hannover, Germany Local Institution Muenchen, Germany Local Institution Ornbau, Germany Local Institution Rotenburg An De Fluda, Germany Local Institution Tuebingen, Germany Local Institution Villingen-Schwenningen, Germany Italy Local Institution Ancona, Italy Local Institution Chieti Scalo, Italy Local Institution Pisa, Italy Local Institution Ravenna, Italy Local Institution Sassari, Italy Norway Local Institution Oslo, Norway Local Institution Snaroya, Norway Russian Federation Local Institution Moscow, Russian Federation Local Institution Saratov, Russian Federation Local Institution St. Petersburg, Russian Federation Local Institution Yaroslavl, Russian Federation Spain Local Institution A Coruna, Spain Local Institution Barcelona, Spain Local Institution Granada, Spain Local Institution Sevilla, Spain Local Institution Zaragoza, Spain Less <<
NCT00362258 Hypertension Phase 4 Completed - Egypt ... More >> Sanofi-Aventis Administrative Office Cairo, Egypt Less <<
NCT00847834 Hypertension Phase 4 Completed - China ... More >> Sanofi aventis administrative office Beijing, China Less <<
NCT00095290 Albuminuria Phase 4 Completed - -
NCT00334581 Hypertension Phase 4 Completed - China ... More >> Sanofi-Aventis Administrative Office Shanghai, China Less <<
NCT00956644 Hypertension Phase 3 Completed - -
NCT00389168 - Completed - -
NCT00517322 Left Atrial Volume ... More >> Hypertensive Heart Disease Antihypertensive Drugs Diastolic Function Renin Angiotensin System Less << Phase 4 Unknown August 2010 Italy ... More >> University of Insubria-Department of Clinical Medicine Recruiting Varese, Italy, 21100 Contact: anna maria grandi, MD    +39+332 278594    amgrandi@libero.it    Contact: anna maria grandi, MD    +39 + 332 278594    amgrandi@libero.it    Sub-Investigator: andrea maria maresca, MD          Sub-Investigator: andrea bertolini, MD          Sub-Investigator: monica gianni, MD          Sub-Investigator: eleonora nicolini, MD Less <<
NCT00389168 Hypertension Phase 2 Phase 3 Completed - Sweden ... More >> Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory Stockholm, Sweden, SE-182 88 Less <<
NCT00249795 Atrial Fibrillation ... More >> Cardiovascular Disease Less << Phase 3 Completed - -
NCT00791830 Kidney Failure, Chronic Phase 3 Completed - Denmark ... More >> Department of Nephrology, Aarhus University, Aalborg Aalborg, Denmark, 9000 Department of Nephrology, Aarhus University Hospital, Skejby Aarhus N, Denmark, 8200 Department of Medicine, Fredericia Hospital Fredericia, Denmark, 7000 Haemodialysis unit, Horsens Hospital Horsens, Denmark, 8700 Hemodialysis Unit, Randers Hospital Randers, Denmark, 8600 Department of Medicine M, Viborg Hospital Viborg, Denmark, 8800 Less <<
NCT00263003 Hypertension Phase 3 Completed - Taiwan ... More >> Sanofi-Aventis Taipei, Taiwan Less <<
NCT01712126 Hypertension Not Applicable Completed - United States, Texas ... More >> Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) San Antonio, Texas, United States, 78217 Less <<
NCT00249795 - Completed - -
NCT00564187 Hypertension Phase 4 Completed - Tunisia ... More >> Sanofi-Aventis Megrine, Tunisia Less <<
NCT01712100 Hypertension Not Applicable Completed - United States, Texas ... More >> Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) San Antonio, Texas, United States, 78217 Less <<
NCT00095394 Hypertension Phase 3 Completed - -
NCT01712113 Hypertension Not Applicable Completed - United States, Texas ... More >> Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) San Antonio, Texas, United States, 78217 Less <<
NCT00957554 Hypertension Phase 3 Completed - -
NCT00265967 Hypertension PHASE4 COMPLETED - Sanofi-Aventis, Istanbul, Turk... More >>ey Less <<
NCT00613496 Persistent Atrial Fibrillation Phase 4 Unknown May 2010 Germany ... More >> University Hospital Magdeburg; Div. of Cardiology Recruiting Magdeburg, Germany, 39120 Contact: Veronika Raetzel    0049 391 6701    veronika.raetzel@medizin.uni-magdeburg.de Less <<
NCT00443612 Hypertension Phase 4 Completed - Taiwan ... More >> Sanofi-Aventis Taipei, Taiwan Less <<
NCT01712139 Hypertension Not Applicable Completed - United States, Texas ... More >> Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) San Antonio, Texas, United States, 78217 Less <<
NCT01825850 Healthy Phase 1 Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of Less <<
NCT00987662 Obesity Hyper... More >>tension Less << Phase 4 Withdrawn(no funding) January 2014 Greece ... More >> Hypertension-24h ABPM Center Papageorgiou Hospital Thessaloniki, Greece Less <<
NCT02842359 Type 2 Diabetes Mellitus Phase 4 Completed - Korea, Republic of ... More >> Korea Seoul, Korea, Republic of Less <<
NCT03147677 Type 2 Diabetic Nephropathy Phase 4 Recruiting December 2018 China, Hunan ... More >> The Third Xiangya Hospital of Central South University Recruiting Changsha, Hunan, China, 410000 Contact: Hao Zhang, Doctor    +86-13975806919    zhanghaoliaoqing@163.com    Hunan Chenzhou NO.1 People's Hospital Recruiting Chenzhou, Hunan, China, 423000 Contact: Xiangpin Liao, bachelor    +81-13507359887    13507359887@139.com    Hunan Yiyang Central Hospital Recruiting Yiyang, Hunan, China, 413000 Contact: Xiaohua Deng, bachelor    +81-13707370981    yoyotyz@126.com Less <<
NCT00352560 Atrial Fibrillation Phase 3 Completed - Spain ... More >> Local Institution Madrid, Spain, 28040 Local Institution Madrid, Spain, 28046 Local Institution Madrid, Spain, 28905 Less <<
NCT03476603 Obesity, Morbid RECRUITING 2025-10-26 St. Olavs University Hospital,... More >> Trondheim, Norway Less <<
NCT01447797 Healthy Phase 1 Completed - Korea, Republic of ... More >> Korea University Anam Hospital Seoul, Korea, Republic of Less <<
NCT00549133 Hypertension|Diabetes Mellitus... More >> Type 2 Less << PHASE4 COMPLETED 2025-04-05 Sanofi-Aventis, Istanbul, Turk... More >>ey Less <<
NCT02386293 Hypertension ... More >>Obesity Stress, Psychological Blood Pressure Less << Phase 2 Recruiting May 2019 United States, Georgia ... More >> Augusta University Recruiting Augusta, Georgia, United States, 30912 Contact: Kimberly Norland    706-721-1755    knorland@augusta.edu    Contact: Sandra Young-Mayes, BS    7067211755    syoungmayes@augusta.edu    Principal Investigator: Gregory A Harshfield, PhD          Sub-Investigator: Ryan A Harris, PhD          Sub-Investigator: Yanbin Dong, MD, PhD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.67mL

2.33mL

1.17mL

23.34mL

4.67mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories